Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
AAIC 2026 | London, United Kingdom
Jul 12 - 15, 2026
Poster
PROTAC LRRK2 Degraders Reduce Pathological Tau and Modulate Endolysosomal–Neuroinflammatory Pathways in Translational Model SystemsFASEB 2026 | Louisville, KY
Jun 1 - 4, 2026
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCLASCO 2026 | Chicago, IL
May 29 - Jun 2, 2026
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCLAACR 2026 | San Diego, CA
Apr 17 - 22, 2026
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCLAACR 2026 | San Diego, CA
Apr 17 - 22, 2026
Poster
Preclinical Antitumor and Immunomodulatory Activity of ARV-6723, a PROTAC HPK1 Degrader, Versus ICIsAACR 2026 | San Diego, CA
Apr 17 - 22, 2026
Poster
Preclinical Efficacy of a PROTAC Pan-KRAS Degrader in a KRAS G12D Syngeneic Mouse Model and Concurrent Immune TME ChangesAD/PD 2026 | Copenhagen, Denmark
Mar 17 - 21, 2026
Presentation
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants With Parkinson’s DiseaseAACR RAS 2026 | Los Angeles, CA
Mar 5 - 8, 2026
Poster
Preclinical Activity of an Orally Bioavailable PROTAC Pan-KRAS Degrader Versus Inhibitors in Mutant KRAS ModelsAACR RAS 2026 | Los Angeles, CA
Mar 5 - 8, 2026